Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPA: RESP30X Nitric Oxide in NCFB Patients
NCT06663176Phase 2Active, not recruiting
- Sponsor
- Thirty Respiratory Limited
- Start
- Oct 2024
- Primary completion
- Feb 2028
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RESP302, ALX1 in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by Thirty Respiratory Limited. Started Oct 2024; status: active, not recruiting.
02
Drugs
RESP302ALX1
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT06663176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663176.